APHIOS® PHARMA LLC

Trevor P. Castor, PhD

President & CEO

Aphios Pharma LLC

Developing cannabis-based, FDA-approved drugs for Cancer Pain, Opioid Use Disorder, Anxiety and Multiple Sclerosis



XPHIOS[®] PH&RM& LLC


Inspired by Nature, Enabled by Science®

- We are dedicated to the discovery, delivery, development and commercialization of cannabis and hemp-based drugs for Central and Peripheral Nervous System disorders
- Our initial product targets are Pain including Cancer Induced Peripheral Neuropathic Pain (CIPNP), Opioid Use Disorder (OUD), Anxiety, and Multiple Sclerosis

Aphios

The Problem: Internal Cannabinoids

- We, as humans, have an inherent endocannabinoid or internal cannabinoid system – anandamide (AEA) is stimulated by fatty acid hydrolase (FAAH) enzyme
- Unbalances in our internal endocannabinoid system can create unbalances in our health and our abilities to respond to negative health intrusions
- Cannabis and hemp can help. Cannabis consists of 60 - 100 bioactive compounds including Δ9-THC and CBD. Hemp primarily contains CBD
- Cannabis/Hemp have complicated interactions with the Peripheral and Central Nervous Systems and can help rebalance our endocannabinoid system



Cannabis Interactions with the Peripheral and Central Nervous Systems

The Problem: Pain, Anxiety, Opioids


- Millions suffer from pain and anxiety
 - 50% of cancer patients experience untreated pain
 - Pain from diseases such as MS, age, and injuries
- Opioids can be an effective treatment, yet Opioid Use
 Disorder is a massive problem
 - Common treatments for Opioid Use Disorder are ineffective
- Cannabis can be an effective treatment, but.



Aphios

The Problem: External Cannabinoids

- When *Cannabis* is smoked or inhaled, cannabinoids are rapidly absorbed. Cannabinoid composition is not consistent making it difficult to dose. The impact is very short-lived or acute and not adequate for chronic use.
- When cannabinoids are taken orally, they are rapidly degraded and excreted from our bodies. They are difficult to administer orally because they are hydrophobic with poor bioavailability (~ 6%) which results in over 90 percent loss from the body
- Cannabinoids can help but we need to keep them in the body longer and protect them from degradation. We can do so by encapsulating cannabinoids in nanoparticles.
- Cancer pain and opioid addiction are only treated with synthetic drugs, such as opioids, that have significant adverse side-effects such as addiction




Bioactivities of Non-Psychotropic Cannabinoids

Aphios

Our Solution: Sustained Release Nanoparticles

- Keep specific, bioactive cannabinoids in the body longer
 - Improve stability from oxygen degradation, and protect from enzymes in digestive tract and stomach acids
 - Prevents first-pass metabolism by liver enzymes, and keep nanoparticles in circulation longer using pegylation
 - Sustained release from breakdown of biodegradable polymers increases bioavailability from ~6%, reduces dosing, improves compliance and efficacy
- Transition acute impact drugs into a sustained release drugs for chronic indications



Aphios

The Market: Opportunity

Market	Pain	Opioid Use Disorder	Anxiety	Multiple Sclerosis
Characteristics	 Chemotherapy induced Peripheral Neuropathic Pain 50% cancer patients 42.4% of pain mkt 	 500K deaths in 2 decades OUD drugs are opioids CBD alleviate cue- induced OUD and satisfies opioid receptors 	 Generalized anxiety disorder Affects 13% people in US Lower productivity, higher drug/alcohol use 	 400K US, 500K EU Neuroinflammation and Neurodegeneration targets
TAM	\$9.9B by 2027	\$4.9B by 2027	\$19.8B by 2028	\$42B by 2028
SAM	\$4.5B by 2027	\$2.5B by 2027	\$2.0B by 2028	\$1B by 2028
Growth Rate	5.6% CAGR	8.7% CAGR	2.4% CAGR	6.3% CAGR



The Market: Competition



Primary competition is **Jazz Pharma** which recently acquired GW Pharma for \$7.2B. We differ from GW Pharma by using proprietary and patented nanotechnology platforms to improve the delivery and efficacy of cannabinoids through oral and topical administration

abbvie

Secondary competition includes pharmaceutical companies with synthetic cannabis drugs such as AbbVie and Par Pharmaceuticals



Tertiary competition includes pharmaceutical companies that have non-cannabis-based drugs against similar disease targets such as Biogen, Sanofi, Pfizer and Merck

Traction: Research & Collaborations

- Development of a Δ9-THC, A Natural Cannabinoid Product, NCI, NIH, and Nanoencapsulated Δ9-THC for Marijuana Addiction, NIDA, NIH
- Development of cGMP Manufacturing Process for CBD from *Cannabis sativa*, NIDA, NIH
- Collaboration with Rhodes Pharma to nanoencapsulate Δ9-THC in biodegradable polymer nanospheres & phospholipid nanosomes
- Collaboration with Alexza Pharmaceuticals to manufacture Δ9-THCA
- Collaboration with Prosulus Pharma to manufacture transdermal patches of Δ9-THC



Aphios' SuperFluids[™] CO₂ Extraction and Chromatography Purification Pilot Plant

Aphios

Traction: Manufacturing & Agreements

- Developed proprietary technologies for manufacturing and nanoencapsulation of pharmaceutical-grade cannabinoids
- Established supercritical fluid manufacturing facility for 1,000 kg pharma-grade cannabinoids per year under cGMP and fullyequipped Schedule I BSL-2 labs
- Inventory of 1.8 kilograms of cannabinoids (CBD, CBDA, Δ 9-THC, Δ 9-THCA, CBG, CBC, CBN)
- Sixteen (16) patents on drug discovery, manufacturing and nanotechnology drug delivery and four (4) pending
- Mutual Nondisclosure Agreements (mNDAs) with GW Pharma, Erie Management Group, Fujimoto Pharmaceuticals



Aphios' SuperFluiids™ Polymer Nanospheres Encapsulation Apparatus

Aphios

Aphios[.]


Traction: Intellectual Property

Proprietary & Copyright © 2021

- > Drug Discovery: US Patent Nos. 6,569,640; 5,854,064
- > Drug Manufacturing: US Patent Nos. 5,750,709; 5,440,055
 - Drug Crystallization: U.S. Patent 6,221,153

> Drug Delivery:

- Biodegradable Polymer Nanospheres: US Patent Nos.
 9,034,347; 8,703,727; 8,629,177; 8,440,614; 8,070,467;
 7,708,915; 7,147,806
- Phospholipid Nanosomes: US Patent Nos. 9,981,238; 8,637,074; 5,776,486; 5,554,382
- Provisional patent applications on drug discovery, manufacturing, delivery, use and route of administration.



Schematic of Aphios' SuperFluiids[™] Polymer Nanospheres Encapsulation Apparatus


Our Team: Management



Dr. Trevor P. Castor President and Chief Executive Officer Over 30 years of diversified business experience in biotechnology



Dr. Judith L. Palmer-Castor Director, Clinical and Regulatory Affairs Over 20 years of regulatory and clinical experience



Aphios

Dr. Val R. Livada

Business Advisor Ret. Senior Lecturer Sloan School of Management, MIT, Cambridge, MA



Ms. Catherine Prillo

Controller Over 30 years of accounting, financial analysis and strategic planning experience

Our Team: Scientific Advisors



Dr. Arthur D. Lander MD/PhD, Neuroscientist Prof. of Developmental and Cell Biology and Biomedical Engineering Univ. of California, Irvine



Dr. Glenn T. Hong Chemical Engineer Founder, Counter-Current Systems MIT grad and Supercritical Fluid Expert



Dr. Gordon M. Cragg

Natural Product Chemist Ex-Chief of the Natural Products Branch, National Cancer Institute (NCI), NIH Currently serving as an NIH Special Volunteer



Dr. Jonathan Steven Alexander

Biologist Professor of Molecular & Cellular Physiology, Medicine & Neurology, Multiple Sclerosis & AD Researcher Louisiana State University

Aphios






"I am enthusiastic about Aphios Pharma's plans to manufacture and deliver cannabinoids for clinical research studies which follow cGMP. Aphios has a proven track record and this latest endeavor represents an important milestone for patients exploring cannabinoid-based therapies... Aphios is clearly invested in facilitating research and clinical endeavors which are likely to advance the science of cannabinoid-based medicines, and with the launch of this program, Aphios stands uniquely poised to make highly significant contributions to science and medicine."

Dr. Staci A. Gruber, Associate Professor of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA

Aphios[®]



"I have read through your SBIR Phase I grant submission titled "Nanoformulation of CBD for Chemotherapy Induced Peripheral Neuropathic Pain (CIPNP)" with attention to your efforts to improve the pharmacokinetics of CBD using Aphios Patented nanoformulation to improve the pharmacodynamics of CBD in a model of CIPN-induced pain. There is a great need for novel medications in CIPN in order to reduce the under-utilization of these effective chemotherapeutics. The neuropathy and pain induced by chemotherapeutics results in dose limiting and incomplete destruction of the cancer.I am excited about and intrigued with the potential of the nanoformulations of CBD."


Dr. Todd W. Vanderah, Professor and Head, Department of Pharmacology, University of Arizona



"We are quite interested and excited about your planned research on nanoencapsulated Cannabidiol (CBD) to develop an "Opioid Addiction Therapeutic." It is my understanding that this product could also have an analgesic effect, thus providing a prophylactic as well as therapeutic role for patients. In 2017, I was appointed by Alabama Governor Robert Bentley to serve on the Governor's Task Force on Opioid Addiction and Abuse. I would be delighted to provide your team with advice on both progressing your molecule to and in the clinic. At that stage, we would explore participating in your clinical trials to bring much needed non-opioid therapeutics to people suffering from Opioid Use Disorder."

Dr. Brent Boyett DMD, DO, DFSAM, Chief Medical Officer and Founder Drug & Alcohol Treatment Centers, Pathway Healthcare

Aphios



"Aphios under the leadership of Dr. Trevor P. Castor has pioneered the application of supercritical fluid technologies: to drug delivery systems, the extraction of bioactive natural and marine products, nanoparticulate synthesis, and more recently in the field of cannabis science & technology. Under Dr. Castor's leadership, Aphios has a successful record of developing extraction and formulation technologies as applied to drugs such as Taxol, THC, several bioactive marine products which will now be focused in this new company on cannabidiol on a nanoscale to achieve solubilization and facilitate sustained release of CBD."

Dr. Jerry W. King, retired University Professor and Supercritical Fluid Technology expert and author, Fayetteville, AR

Our Plan: Development Strategy

- Isolate and manufacture specific cannabis drugs using patented environmentally-friendly supercritical carbon dioxide extraction and chromatographic purification technologies
- Nanoencapsulate these drugs in biodegradable polymer nanospheres utilizing patented supercritical fluid technologies to significantly improve <u>oral</u> bioavailability and sustain release over 8-24 hours
- Conduct **rigorous Phase 2 clinical trials** to demonstrate safety and efficacy



Aphios' SuperFluids[™] Critical Fluid Fractionation (SFS-CXF) Technology

Aphios

Our Plan: Development Strategy

	Y01	Y02	Y03	Y04
Manufacturing of Pharmaceutical Grade CBD				
Scale-up of Polymer Nanospheres (PNS™) Technology				
Nanoencapsulation of Purified CBD				
In Vitro and In Vivo Studies				
Investigational New Drug (IND) Enabling Studies				
File IND with the FDA for Nanoencapsulated Cannabinoids				
Conduct Phase 2 Clinical Trials under 505b(2) Pathway				
Conduct Phase 3 Pivotal Clinical Trials on Safety & Efficacy				
Obtain FDA approval of New Drug Application (NDA)				

Aphios[•]

Our Plan: Funding History, Ask and Exit

Spent by Aphios Corporation to develop enabling technology platforms and knowledge used in the manufacturing and nanoencapsulation of cannabinoids

In peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and National Center for Complimentary and Integrative Health, NIH

\$1 M

\$46

Μ

\$7.9

Μ

Crowdfunding of \$1M to continue development studies and fund raising to raise up to \$30M for cGMP manufacturing, conduct IND-enabling studies, file an IND with the FDA and conduct Phase 2 clinical trials

Exit

Investors will be able to exit in 3 years in a M&A in 2025. Alternatively, we plan to do an IPO to raise \$100M in 2026 to complete clinical trials and file an NDA with the FDA



Our Plan: Exit Strategy

- Aphios Pharma LLC strategic commercialization and exit plans will follow one or more of three strategic options:
 - (1) Establish a strategic corporate partnership or M&A with a multinational pharmaceutical company such as Jazz Pharma, Merck, Biogen, AbbVie, Pfizer to develop and commercialize nanocannabinoids on a world-wide basis.
 - (2) In this option, we will seek to out-license nanocannabinoids as early as possible in the development cycle, on a regional basis.
 - (3) In this option, we will raise \$100M in an IPO to continue clinical development and commercialization of nanocannabinoids for CIPNP, anxiety, opioid use disorder, and/or Multiple Sclerosis
- Investors in the A round can exit on the execution of an M&A in Option 1 or IPO in Option 3





Potential Acquirers

nhios

Proprietary & Copyright © 2021

MERCK

Exit Strategy: Multiple Opportunities



Aphios[®]

Proprietary & Copyright © 2021

Thank you for Your Interest

APHIOS® PHARMA LLC

Dr. Trevor P. Castor, CEO

- Massive problem and opportunity
- Vastly experienced team and key support
- Proprietary and patented nanotechnology
- Benefitting from decades of development
- Multiple exit opportunities